Bégué P, Michel B, Chasalette J P, Allouche G, Quinet B
Pathol Biol (Paris). 1986 May;34(5):525-9.
The pharmacokinetics and clinical efficacy of ceftazidime, a new cephalosporin with activity against Pseudomonas aeruginosa, were studied in children and neonates. Our studies suggest that ceftazidime should be considered for the treatment of sever infections in pediatric patients (neonatal septicemia and meningitis, urinary tract infections due to multiresistant bacteria) and for the empirical therapy of febrile episodes in immunocompromised children. Ceftazidime appears to be effective and safe, alone or associated with an aminoglycoside, in the treatment of acute exacerbation in cystic fibrosis. The dosage recommended on the basis of our pharmacokinetic studies is 30 to 50 mg/kg intravenously every eight hours for infants and children and 30 mg/kg every 12 hours for neonates. Larger doses should be used in cystic fibrosis patients, immunosuppressed children, meningitis, and bacterial infections due to organisms with high MICs.
头孢他啶是一种对铜绿假单胞菌有活性的新型头孢菌素，对儿童和新生儿的药代动力学及临床疗效进行了研究。我们的研究表明，对于儿科患者的严重感染（新生儿败血症和脑膜炎、多重耐药菌引起的尿路感染）以及免疫功能低下儿童发热发作的经验性治疗，应考虑使用头孢他啶。头孢他啶单独使用或与氨基糖苷类药物联合使用，在治疗囊性纤维化急性加重时似乎有效且安全。根据我们的药代动力学研究，推荐的剂量为婴儿和儿童每8小时静脉注射30至50mg/kg，新生儿每12小时30mg/kg。囊性纤维化患者、免疫抑制儿童、脑膜炎以及由高MICs病原体引起的细菌感染患者应使用更大剂量。
